SGRL
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Shree Ganesh Remedies Commissions 2.5 MW Solar Power Project
March 25 (Reuters) - Shree Ganesh Remedies Ltd SEEG.BO:
SHREE GANESH REMEDIES LTD - COMMISSIONS 2.5 MW SOLAR POWER PROJECT
Source text: ID:nBSE5mttNB
Further company coverage: SEEG.BO
(([email protected];;))
March 25 (Reuters) - Shree Ganesh Remedies Ltd SEEG.BO:
SHREE GANESH REMEDIES LTD - COMMISSIONS 2.5 MW SOLAR POWER PROJECT
Source text: ID:nBSE5mttNB
Further company coverage: SEEG.BO
(([email protected];;))
India's Shree Ganesh Remedies jumps on signing supply agreement
** Shares of pharmaceuticals co Shree Ganesh Remedies SEEG.BO rise 11.5% to 826.80 rupees
** Co signs three-year supply agreement with a Japanese company to manufacture three products
** Agreement has potential for extension by additional two years
** Co did not disclose name of the client, or provide financial details
** Trading vols more than 8x the 30-day average
** SEEG fell 7% in 2024
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of pharmaceuticals co Shree Ganesh Remedies SEEG.BO rise 11.5% to 826.80 rupees
** Co signs three-year supply agreement with a Japanese company to manufacture three products
** Agreement has potential for extension by additional two years
** Co did not disclose name of the client, or provide financial details
** Trading vols more than 8x the 30-day average
** SEEG fell 7% in 2024
(Reporting by Vijay Malkar)
(([email protected];))
Shree Ganesh Remedies Signs Long-Term Supply Agreement With Japanese Company
Jan 30 (Reuters) - Shree Ganesh Remedies Ltd SEEG.BO:
SIGNS LONG-TERM SUPPLY AGREEMENT WITH JAPANESE COMPANY
INITIAL TERM OF AGREEMENT FOR THREE YEARS, POTENTIAL FOR EXTENSION BY TWO YEARS
CO TO MANUFACTURE THREE INNOVATIVE PRODUCTS UNDER AGREEMENT
Source text: ID:nBSE9gK6GL
Further company coverage: SEEG.BO
(([email protected];;))
Jan 30 (Reuters) - Shree Ganesh Remedies Ltd SEEG.BO:
SIGNS LONG-TERM SUPPLY AGREEMENT WITH JAPANESE COMPANY
INITIAL TERM OF AGREEMENT FOR THREE YEARS, POTENTIAL FOR EXTENSION BY TWO YEARS
CO TO MANUFACTURE THREE INNOVATIVE PRODUCTS UNDER AGREEMENT
Source text: ID:nBSE9gK6GL
Further company coverage: SEEG.BO
(([email protected];;))
Shree Ganesh Remedies Receipt Revocation Of Closure Direction By Gujarat Pollution Control Board
Aug 22 (Reuters) - Shree Ganesh Remedies Ltd SEEG.BO:
RECEIPT REVOCATION OF CLOSURE DIRECTION BY GUJARAT POLLUTION CONTROL BOARD
CO RECEIVED REVOCATION LETTER FROM GPCB FOR ANKLESHWAR FACILITY
Source text for Eikon: ID:nBSE9bJkRz
Further company coverage: SEEG.BO
(([email protected];))
Aug 22 (Reuters) - Shree Ganesh Remedies Ltd SEEG.BO:
RECEIPT REVOCATION OF CLOSURE DIRECTION BY GUJARAT POLLUTION CONTROL BOARD
CO RECEIVED REVOCATION LETTER FROM GPCB FOR ANKLESHWAR FACILITY
Source text for Eikon: ID:nBSE9bJkRz
Further company coverage: SEEG.BO
(([email protected];))
Shree Ganesh Remedies Says Incorporated Unit "SGRL USA INC"
Aug 24 (Reuters) - Shree Ganesh Remedies Ltd SEEG.BO:
INCORPORATED UNIT "SGRL USA INC"
Source text for Eikon: ID:nBSE3pkJzJ
Further company coverage: SEEG.BO
(([email protected];))
Aug 24 (Reuters) - Shree Ganesh Remedies Ltd SEEG.BO:
INCORPORATED UNIT "SGRL USA INC"
Source text for Eikon: ID:nBSE3pkJzJ
Further company coverage: SEEG.BO
(([email protected];))
Events:
Dividend
Rights
Dividend
Bonus
Dividend
Bonus
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Shree Ganesh Remed. do?
Shree Ganesh Remedies produces and supplies drug intermediates and specialty chemicals for the pharmaceutical industry. Their product range includes items related to antipsychotic, antiseptic, deprotonation reactions, hyperlipidemia, alzheimers, and anti-viral drugs.
Who are the competitors of Shree Ganesh Remed.?
Shree Ganesh Remed. major competitors are NGL Fine-Chem, Acutaas Chemicals, Kopran, Nectar Lifesciences, SMS Lifesciences, Themis Medicare, Everest Organics. Market Cap of Shree Ganesh Remed. is ₹772 Crs. While the median market cap of its peers are ₹644 Crs.
Is Shree Ganesh Remed. financially stable compared to its competitors?
Shree Ganesh Remed. seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Shree Ganesh Remed. pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Shree Ganesh Remed. latest dividend payout ratio is 4.12% and 3yr average dividend payout ratio is 4.3%
How has Shree Ganesh Remed. allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Shree Ganesh Remed. balance sheet?
Balance sheet of Shree Ganesh Remed. is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Shree Ganesh Remed. improving?
The profit is oscillating. The profit of Shree Ganesh Remed. is ₹23.07 Crs for TTM, ₹28.11 Crs for Mar 2024 and ₹15.18 Crs for Mar 2023.
Is the debt of Shree Ganesh Remed. increasing or decreasing?
Yes, The net debt of Shree Ganesh Remed. is increasing. Latest net debt of Shree Ganesh Remed. is ₹28.21 Crs as of Mar-25. This is greater than Mar-24 when it was ₹3.79 Crs.
Is Shree Ganesh Remed. stock expensive?
Shree Ganesh Remed. is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Shree Ganesh Remed. is 33.48, while 3 year average PE is 30.82. Also latest EV/EBITDA of Shree Ganesh Remed. is 20.41 while 3yr average is 21.55.
Has the share price of Shree Ganesh Remed. grown faster than its competition?
Shree Ganesh Remed. has given better returns compared to its competitors. Shree Ganesh Remed. has grown at ~35.91% over the last 3yrs while peers have grown at a median rate of 17.93%
Is the promoter bullish about Shree Ganesh Remed.?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Shree Ganesh Remed. is 72.8% and last quarter promoter holding is 72.8%.
Are mutual funds buying/selling Shree Ganesh Remed.?
There is Insufficient data to gauge this.